Navigation Links
Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting

CINCINNATI, June 16, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced several of its senior clinical development experts will present on important industry issues at the Drug Information Association (DIA) 47th Annual Meeting, June 19-23, 2011, in Chicago. Kendle experts will address key topics, including the benefits of hybrid monitoring; finding an economic balance between cost and reimbursement; and strategic development planning for clinical trials programs. Company executives will be available throughout the conference at booth #1343 for on-site meetings and to discuss why partnering with Kendle is an important step toward clinical development project success.

The 2011 DIA Annual Meeting bills itself as the "largest global, multidisciplinary gathering of biopharmaceutical professionals whose agenda is clear: to find immediate solutions to the most pressing needs of our industry for today and tomorrow." With the cost of drug development today estimated at well over $1 billion, the biopharmaceutical industry is under immense and growing pressure to drive efficiencies into the clinical development process and control costs. Partnering with global CROs, such as Kendle, that offer strong geographic, therapeutic and functional expertise across Phase I through IV is an important part of the solution. Independent research by the Tufts Center for the Study of Drug Development indicates clinical trials conducted by CROs are completed an average of 30 percent more quickly than those conducted in-house, resulting in an average time savings of four to five months and translating to $120 million to $150 million in increased revenue potential.

Kendle Speakers at DIA:

Tuesday, June 21, 10-11:30 a.m., Session 213, Room W181a
Symposium: Monitoring and Source Verification: New Approaches to Quality
Title: Producing Quality Data for Clinical Trials: Is Full Onsite Monitoring the Only Answer?
Lisa Gorman, CCRR
Director, Clinical Operations – Project Coordination Services

Wednesday, June 22, 1:30-3 p.m., Session 358, Room W184d
Symposium: Using Real-world Data for Making Real-world Decisions
Title: In-patient Cost and Reimbursement for Patients with Progressive Malignant Thoracic
Neoplasm in Germany
Florian Eichmann, PhD, MSc
Director, Registries and Health Outcomes

Thursday, June 23, 9-10:30 a.m., Session 402, Room W474b
Workshop: Strategic Development Planning: Designing Fast and Efficient Programs
William K. Sietsema, PhD
Vice President, Regulatory Consulting and Submissions

About Kendle
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

For more information, please visit

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the value of partnering with Kendle. Words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may," and other similar expressions are intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of Kendle's management and involve a number of significant risks and uncertainties, many of which are difficult to predict and are generally beyond the control of Kendle. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional factors that could cause Kendle's results to differ materially from those described in the forward-looking statements can be found in the periodic reports filed with the Securities and Exchange Commission, which are available at the Securities and Exchange Commission's website ( at no charge. Kendle assumes no responsibility to update any forward-looking statements as a result of new information or future developments except as expressly required by law.

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2010 Earnings Conference Call and Webcast
2. Kendle Announces Third Quarter 2010 Results
3. Kendle to Present at Robert W. Baird & Co. 2010 Health Care Conference
4. Kendle Appoints Jeffrey M. Zucker to Lead Global Patient Recruitment Efforts
5. Kendle Rated a Top CRO to Work with for Fourth Consecutive Year
6. Kendle Announces New Revolving Credit Facility
7. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
8. Kendle to Present at UBS Global Life Sciences Conference
9. Kendle to Present at Robert Baird 2009 Health Care Conference
10. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
11. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):